MCID: ELP001
MIFTS: 41

Elephantiasis

Categories: Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Elephantiasis

MalaCards integrated aliases for Elephantiasis:

Name: Elephantiasis 11 75 53 2 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:4976
MeSH 43 D004604
NCIt 49 C34569
SNOMED-CT 68 155485008
UMLS 71 C0013882

Summaries for Elephantiasis

CDC: 2 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

MalaCards based summary: Elephantiasis is related to podoconiosis and filarial elephantiasis. An important gene associated with Elephantiasis is ELANE (Elastase, Neutrophil Expressed), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Doxycycline and Glycerin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and lymph node.

Wikipedia: 75 Elephantiasis is the enlargement and hardening of limbs or body parts due to tissue swelling. It is... more...

Related Diseases for Elephantiasis

Diseases related to Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
# Related Disease Score Top Affiliating Genes
1 podoconiosis 32.7 TVP23C STH CDRT4
2 filarial elephantiasis 31.4 VEGFC STH IL5 IL4 IL13 IL10
3 loiasis 31.2 STH IL5 IL4 IL13 IL10
4 lymphangitis 30.3 VEGFC FLT4 CD4
5 chlamydia 30.2 IL5 IL4 IL10
6 filariasis 30.2 STH IL5 IL4 IL13 IL10 GPT2
7 cellulitis 30.1 RNASE3 IL5 FLT4 CD4
8 leishmaniasis 30.1 IL5 IL4 IL13 IL10
9 onchocerciasis 30.0 STH RNASE3 IL5 IL4 IL13 ELANE
10 congenital lymphedema 29.9 VEGFC FLT4
11 actinomycosis 29.9 IL10 CD4
12 leprosy 3 29.9 IL5 IL4 IL13 IL10 CD4
13 systemic scleroderma 29.9 IL4 IL13 IL10 CD4
14 dermatitis 29.9 RNASE3 IL5 IL4 IL13 IL10
15 tertiary syphilis 29.7 IL10 CD4
16 dysentery 29.7 STH IL10 CD4
17 plague 29.7 IL4 IL10 CD4
18 trypanosomiasis 29.6 IL4 IL10 CD4
19 fungal infectious disease 29.6 IL5 IL4 IL13 IL10 CD4
20 tetanus 29.6 IL5 IL4 IL13 IL10
21 schistosomiasis 29.4 RNASE3 IL5 IL4 IL13 IL10
22 bone inflammation disease 29.4 IL4 IL13 IL10 CD4
23 lymphangioma 29.3 VEGFC IL10 FLT4 CD4
24 cutaneous leishmaniasis 29.2 IL5 IL4 IL13 IL10 CD4
25 crohn's disease 29.2 IL5 IL4 IL13 IL10 CD4
26 parasitic helminthiasis infectious disease 29.1 STH RNASE3 IL5 IL4 IL13 IL10
27 common cold 29.0 RNASE3 IL5 IL4 IL13 IL10 CD4
28 ascaris lumbricoides infection 29.0 STH IL5 IL4 IL13 IL10 CD4
29 contact dermatitis 29.0 RNASE3 IL5 IL4 IL13 IL10 CD4
30 psoriasis 29.0 IL5 IL4 IL13 IL10 ELANE CD4
31 respiratory failure 28.9 RNASE3 IL5 IL4 IL13 IL10 ELANE
32 malaria 28.8 RNASE3 IL5 IL4 IL13 IL10 ELANE
33 skin disease 28.8 RNASE3 NF1 IL5 IL4 IL13 IL10
34 connective tissue disease 28.7 NF1 IL5 IL4 IL13 IL10 ELN
35 eye disease 28.3 VEGFC NF1 IL5 IL4 IL13 IL10
36 hereditary lymphedema i 10.7
37 neurofibromatosis 10.4
38 neurofibromatosis-noonan syndrome 10.4
39 erysipelas 10.4
40 cerebral aneurysms 10.4 ELN ELANE
41 neurofibromatosis, type i 10.3
42 loeffler endocarditis 10.3 RNASE3 IL5
43 lymphogranuloma venereum 10.3
44 neurofibroma 10.3
45 cercarial dermatitis 10.2 IL5 IL4
46 venous insufficiency 10.2
47 congestive heart failure 10.2
48 kimura disease 10.2 RNASE3 IL5 IL4
49 periodontitis 10.2 IL4 IL10 ELANE
50 enterobiasis 10.2 STH IL5 IL4

Graphical network of the top 20 diseases related to Elephantiasis:



Diseases related to Elephantiasis

Symptoms & Phenotypes for Elephantiasis

Drugs & Therapeutics for Elephantiasis

Drugs for Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
2
Glycerin Approved, Investigational Phase 3 56-81-5 753
3
Petrolatum Approved, Investigational Phase 3 8009-03-8
4
Artenimol Approved, Experimental, Investigational Phase 3 71939-50-9 540327
5
Piperaquine Approved, Experimental, Investigational Phase 3 4085-31-8
6
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
7
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
8
Moxidectin Approved, Investigational, Vet_approved Phase 3 113507-06-5 72728820
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10 Eusol Phase 3
11
Sodium Hypochlorite Phase 3
12 Protective Agents Phase 3
13 Antimalarials Phase 3
14 Citrate Phase 3
15
Mebendazole Approved, Vet_approved 31431-39-7 4030
16
Piperazine Approved, Vet_approved 110-85-0 4837
17
Permethrin Approved, Investigational 52645-53-1 40326
18 Calcium, Dietary
19 Anticoagulants
20 Piperazine citrate
21 DMP 777 157341-41-8
22 Chelating Agents
23 Liver Extracts
24
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Completed NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
6 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
7 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
8 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
9 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929121 Phase 3 Doxycycline;Placebo
10 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
11 Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial Recruiting NCT04844905 Phase 3 Ivermectin;Placebo;Dihydroartemisinin-piperaquine
12 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Active, not recruiting NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
13 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
14 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
15 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
16 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
17 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
20 Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug Not yet recruiting NCT05084560 Phase 1 AWZ1066S;Placebo
21 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Unknown status NCT04258670
22 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
23 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
24 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
25 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
26 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
27 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
28 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
29 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
30 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
31 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
32 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
33 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
34 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
35 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
36 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
37 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
38 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
39 Research for Elimination of Human Filariasis Completed NCT00145223
40 Exhaled NO Testing in Filariasis Completed NCT01628497
41 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
42 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;albendazole 800mg and ivermectin 400mcg/kg bi-annually
43 Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches Terminated NCT01939431

Search NIH Clinical Center for Elephantiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ivermectin

Genetic Tests for Elephantiasis

Anatomical Context for Elephantiasis

Organs/tissues related to Elephantiasis:

MalaCards : Skin, Liver, Lymph Node, Bone Marrow, Adrenal Cortex, T Cells, Bone

Publications for Elephantiasis

Articles related to Elephantiasis:

(show top 50) (show all 1537)
# Title Authors PMID Year
1
Circulating fibrosis markers, eosinophil cationic protein and eosinophil protein X in patients with Wuchereria bancrofti infection: association with clinical status. 53 62
16800126 2006
2
Saxophone penis - An intriguing manifestation of gastrointestinal metastasis. 62
36352346 2022
3
Hemorrhagic shock due to ruptured lower limb vascular malformation in a neurofibromatosis type 1 patient: A case report. 62
36387817 2022
4
Filariasis in an alcoholic male-coincidental or causal association? 62
36318173 2022
5
Unilateral Lower Extremity Elephantiasis. 62
36449404 2022
6
Clinical impact of selumetinib on pediatric elephantiasis neuromatosa. 62
35739628 2022
7
Health-related quality of life and associated factors among adult podoconiosis patients in Debre Elias district Northwest, Ethiopia. 62
36054193 2022
8
[Elephantiasis of the lower limb: Treatment of seven cases using the modified Charles technique]. 62
35927107 2022
9
Elephantiasis in a patient with thyroid eye disease. 62
33349089 2022
10
Unusual coexistence of Stewart-Treves syndrome and sickle cell anaemia: a case of dual pathology. 62
35793854 2022
11
The potentials of Calotropis procera against filarial elephantiasis: an in-silico approach. 62
35692472 2022
12
An integrative therapeutic approach to elephantiasis nostras verrucosa: A case report. 62
35317434 2022
13
Radical reduction and reconstruction for male genital elephantiasis: Superficial circumflex iliac artery perforator (SCIP) lymphatic flap transfer after elephantiasis tissue resection. 62
34756554 2022
14
Podoconiosis instruction at nursing schools in Kenya, Rwanda, and Uganda. 62
35148785 2022
15
Elephantiasis nostras verrucosa in skin of color. 62
34510427 2022
16
Giant scrotal elephantiasis in a migrant from Niger. 62
34331601 2022
17
Eosinophils in filarial infections: Inducers of protection or pathology? 62
36389745 2022
18
Self-Care Practice and Its Associated Factors Among Podoconiosis Patients in East Gojjam Zone, North West Ethiopia. 62
35958889 2022
19
Distinct N-Linked Immunoglobulin G Glycosylation Patterns Are Associated With Chronic Pathology and Asymptomatic Infections in Human Lymphatic Filariasis. 62
35401511 2022
20
Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania. 62
35045109 2022
21
Concomitance of Elephantiasis Nostras Verrucosa and Systemic Sclerosis. 62
32804751 2021
22
Lymphatic filariasis vaccine development: neglected for how long? 62
34633881 2021
23
Functional genomics and metabolomics advance the ethnobotany of the Samoan traditional medicine "matalafi". 62
34725148 2021
24
Resection and reconstruction of idiopathic scrotal elephantiasis: surgical approach and quality of life assessment. 62
34706911 2021
25
Efficacy and side effects of bio-fabricated sardine fish scale silver nanoparticles against malarial vector Anopheles stephensi. 62
34599250 2021
26
Podoconiosis: A Possible Cause of Lymphedema in Micronesia. 62
34522890 2021
27
Hybrid Treatment Combining Lymphaticovenous Anastomoses and the Oriental Herbal Medicine Bofutsushosan for Obesity-Associated Lower Leg Elephantiasis Nostras Verrucosa: A Case Report. 62
32519905 2021
28
Systematic review of Ethiopian medicinal plants used for their anti-inflammatory and wound healing activities. 62
33989738 2021
29
Arteriovenous Malformations in the Setting of Giant Elephantiasis Neuromatosa. 62
34218851 2021
30
A review on the interactions between dendritic cells, filarial parasite and parasite-derived molecules in regulating the host immune responses. 62
33247468 2021
31
[Physiopathology of vulvar elephantiasis of filarial origin. A case report]. 62
33726892 2021
32
Visual Dermatology: Elephantiasis Nostras Verrucosa. 62
32442017 2021
33
Successful surgical resection and reconstruction of scrotal elephantiasis. 62
33718810 2021
34
A late diagnosis of hyperhomocysteinemia with probable evolution to verrucous elephantiasis nostra and leg ulcers. 62
33581929 2021
35
A Case of Elephantiasis Nostras Verrucosa Secondary to Lymphedema Praecox Complicated by Congestive Cardiac Failure. 62
33714971 2021
36
The Eagle effect in the Wolbachia-worm symbiosis. 62
33627171 2021
37
Improved Psychosocial Status after Surgery for Genital Elephantiasis due to Hidradenitis Suppurativa: A Prospective Study of a Case Series. 62
33470416 2021
38
Dual RNAseq analyses at soma and germline levels reveal evolutionary innovations in the elephantiasis-agent Brugia malayi, and adaptation of its Wolbachia endosymbionts. 62
33406151 2021
39
Weeping wounds and sepsis: a complication of elephantiasis nostras verrucosa. 62
33495168 2021
40
Ivermectin, a potential anticancer drug derived from an antiparasitic drug. 62
32971268 2021
41
Scrotal Lymphangiectasia with Penile Elephantiasis in Underlying Lymphatic Filariasis-Challenging the Diagnostic Mind! A Case Report. 62
33401419 2021
42
Assessment of Etiology of Elephantiasis and Its Associated Risk Factors in Jeldu District, West Shoa, Ethiopia. 62
33936214 2021
43
The story of Lymphatic Filariasis elimination as a public health problem from Yemen. 62
32828916 2020
44
Elimination of Lymphatic Filariasis in Shandong Province, China, 1957-2015. 62
32795160 2020
45
Biodiversity of mosquitoes and Mansonia uniformis as a potential vector of Wuchereria bancrofti in Hulu Sungai Utara District, South Kalimantan, Indonesia. 62
33488003 2020
46
A rare presentation of elephantiasis involving vulvae in an Indian female. 62
32525103 2020
47
A case of elephantiasis nostras verrucosa treated successfully by a new type of compressive garment. 62
32981199 2020
48
Urological infections in the developing world: an increasing problem in developed countries. 62
32108257 2020
49
Pancytopenia: a rare cause for a common presentation. 62
32539585 2020
50
Unravelling the Biological Activities of the Byttneria pilosa Leaves Using Experimental and Computational Approaches. 62
33076534 2020

Variations for Elephantiasis

Expression for Elephantiasis

Search GEO for disease gene expression data for Elephantiasis.

Pathways for Elephantiasis

Pathways related to Elephantiasis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 VEGFC NF1 IL5 IL4 IL13 IL10
2
Show member pathways
13.4 VEGFC IL5 IL4 IL13 IL10 FLT4
3
Show member pathways
13.28 VEGFC IL5 IL4 IL13 IL10 FLT4
4
Show member pathways
13.16 VEGFC IL5 IL4 IL13 IL10 FLT4
5
Show member pathways
12.49 FLT4 IL10 IL13 IL4 IL5 VEGFC
6
Show member pathways
12.02 IL5 IL4 IL10 CD4
7 11.86 IL5 IL4 IL10 CD4
8 11.81 IL4 IL13 IL10
9 11.75 IL5 IL4 IL13 IL10
10 11.65 IL5 IL4 IL13
11 11.59 IL5 IL4 IL10
12 11.56 IL5 IL4 IL13 ELN
13 11.56 IL5 IL4 IL13 IL10 CD4
14 11.52 IL10 IL4 IL5
15
Show member pathways
11.48 IL5 IL4 IL13 IL10
16 11.22 IL5 IL4 IL13 IL10 CD4
17 11.21 IL5 IL4 IL13
18 11.04 IL5 IL4 IL13 IL10
19
Show member pathways
10.82 VEGFC FLT4
20 10.82 ELN FLT4 IL10 IL13 IL4 IL5
21 10.82 IL5 IL4 IL13 IL10 CD4
22 10.78 IL4 CD4
23 10.69 IL5 IL4 IL13
24 10.45 VEGFC IL5 IL4 IL13 IL10

GO Terms for Elephantiasis

Biological processes related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.97 IL4 IL13 IL10 ELANE
2 positive regulation of B cell proliferation GO:0030890 9.88 IL5 IL4 IL13
3 type 2 immune response GO:0042092 9.73 IL4 IL10
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.73 IL10 IL13 IL4
5 regulation of isotype switching GO:0045191 9.62 IL4 IL10
6 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
7 positive regulation of immunoglobulin production GO:0002639 9.43 IL5 IL13 IL10
8 positive regulation of endothelial cell proliferation GO:0001938 9.23 VEGFC NF1 IL10 FLT4

Molecular functions related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.23 VEGFC IL5 IL4 IL10

Sources for Elephantiasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....